Executive Summary

1. Nanomedicine platform: designed to substantially advance oncology safety and effectiveness.
2. ONX-1006: sustained nanoparticle paclitaxel with significantly reduced systemic toxicity and no treatment-related adverse effects at the preclinical NOAEL.
3. Efficacy: modeling suggests 90–100% tumor elimination over one year, with a clinical goal of 70% one-year survival.
4. Scalable nanomedicine manufacturing: standardized process established with 15 kg successfully produced.

View or download the full Executive Summary below.

To learn more about Onselex or discuss an investment or strategic partnership opportunity, please contact us.

Company Video:
https://onselex.com/en/sub/sub04_01.php?boardid=newsen&mode=view&idx=7

Contact:
CureCancer@OnSelex.com